Clinical characteristics of the study population at the time of the AF transcatheter ablation
| . | Total population n = 766 patients (%) . | ON-OAT group n = 267 patients (%) . | OFF-OAT group n = 499 patients (%) . | P value . |
|---|---|---|---|---|
| Male sex | 612 (79.9) | 192 (71.9) | 420 (84.2) | <0.01 |
| Age, years ± SD | 57 ± 11 | 61 ± 10 | 55 ± 11 | 0.021 |
| Paroxysmal AF | 326 (42.6) | 91 (34.1) | 235 (47.1) | <0.01 |
| Persistent AF | 440 (57.4) | 176 (65.9) | 264 (52.9) | <0.01 |
| Structural heart disease | 69 (9.0) | 33 (12.4) | 36 (7.2) | 0.026 |
| Congestive heart failure | 28 (3.7) | 17 (6.4) | 11 (2.2) | |
| Hypertension | 362 (47.3) | 161 (60.3) | 201 (40.3) | |
| Age ≥ 65 years | 216 (28.2) | 117 (43.8) | 99 (19.8) | |
| Age ≥ 75 years | 23 (3.0) | 13 (4.9) | 10 (2.0) | |
| Diabetes | 32 (4.2) | 15 (5.6) | 17 (3.4) | |
| Previous stroke/TIA | 69 (9.0) | 53 (19.9) | 16 (3.2) | |
| Female sex | 154 (20.1) | 75 (28.1) | 79 (15.8) | |
| Vascular disease | 74 (9.7) | 35 (13.1) | 39 (7.8) | |
| Liver and/or kidney disease | 3 (0.4) | 2 (0.7) | 1 (0.2) | |
| Bleeding | 2 (0.3) | 2 (0.7) | 0 (0.0) | |
| Drugs and/or alcohol | 90 (11.7) | 20 (7.4) | 70 (14.0) | |
| Labile INR | 122 (15.9) | 122 (45.7) | – | |
| CHADS2 score | <0.01 | |||
| ≤1 | 646 (84.3) | 188 (70.4) | 458 (91.8) | |
| ≥2 | 120 (15.7) | 79 (29.6) | 41 (8.2) | |
| ≥3 | 43 (5.6) | 34 (12.7) | 9 (1.8) | |
| CHA2DS2VASc score | <0.01 | |||
| ≤1 | 478 (62.4) | 101 (37.8) | 377 (75.6) | |
| ≥2 | 288 (37.6) | 166 (62.2) | 122 (24.5) | |
| ≥3 | 127 (16.6) | 87 (32.6) | 40 (8.0) | |
| HASBLED score | <0.01 | |||
| ≤1 | 605 (79.0) | 159 (59.6) | 446 (89.4) | |
| ≥2 | 161 (21.0) | 108 (40.4) | 53 (10.6) | |
| . | Total population n = 766 patients (%) . | ON-OAT group n = 267 patients (%) . | OFF-OAT group n = 499 patients (%) . | P value . |
|---|---|---|---|---|
| Male sex | 612 (79.9) | 192 (71.9) | 420 (84.2) | <0.01 |
| Age, years ± SD | 57 ± 11 | 61 ± 10 | 55 ± 11 | 0.021 |
| Paroxysmal AF | 326 (42.6) | 91 (34.1) | 235 (47.1) | <0.01 |
| Persistent AF | 440 (57.4) | 176 (65.9) | 264 (52.9) | <0.01 |
| Structural heart disease | 69 (9.0) | 33 (12.4) | 36 (7.2) | 0.026 |
| Congestive heart failure | 28 (3.7) | 17 (6.4) | 11 (2.2) | |
| Hypertension | 362 (47.3) | 161 (60.3) | 201 (40.3) | |
| Age ≥ 65 years | 216 (28.2) | 117 (43.8) | 99 (19.8) | |
| Age ≥ 75 years | 23 (3.0) | 13 (4.9) | 10 (2.0) | |
| Diabetes | 32 (4.2) | 15 (5.6) | 17 (3.4) | |
| Previous stroke/TIA | 69 (9.0) | 53 (19.9) | 16 (3.2) | |
| Female sex | 154 (20.1) | 75 (28.1) | 79 (15.8) | |
| Vascular disease | 74 (9.7) | 35 (13.1) | 39 (7.8) | |
| Liver and/or kidney disease | 3 (0.4) | 2 (0.7) | 1 (0.2) | |
| Bleeding | 2 (0.3) | 2 (0.7) | 0 (0.0) | |
| Drugs and/or alcohol | 90 (11.7) | 20 (7.4) | 70 (14.0) | |
| Labile INR | 122 (15.9) | 122 (45.7) | – | |
| CHADS2 score | <0.01 | |||
| ≤1 | 646 (84.3) | 188 (70.4) | 458 (91.8) | |
| ≥2 | 120 (15.7) | 79 (29.6) | 41 (8.2) | |
| ≥3 | 43 (5.6) | 34 (12.7) | 9 (1.8) | |
| CHA2DS2VASc score | <0.01 | |||
| ≤1 | 478 (62.4) | 101 (37.8) | 377 (75.6) | |
| ≥2 | 288 (37.6) | 166 (62.2) | 122 (24.5) | |
| ≥3 | 127 (16.6) | 87 (32.6) | 40 (8.0) | |
| HASBLED score | <0.01 | |||
| ≤1 | 605 (79.0) | 159 (59.6) | 446 (89.4) | |
| ≥2 | 161 (21.0) | 108 (40.4) | 53 (10.6) | |
AF, atrial fibrillation; OAT, oral anticoagulation therapy; TIA, transient ischaemic attack; INR, international normalized ratio.
Clinical characteristics of the study population at the time of the AF transcatheter ablation
| . | Total population n = 766 patients (%) . | ON-OAT group n = 267 patients (%) . | OFF-OAT group n = 499 patients (%) . | P value . |
|---|---|---|---|---|
| Male sex | 612 (79.9) | 192 (71.9) | 420 (84.2) | <0.01 |
| Age, years ± SD | 57 ± 11 | 61 ± 10 | 55 ± 11 | 0.021 |
| Paroxysmal AF | 326 (42.6) | 91 (34.1) | 235 (47.1) | <0.01 |
| Persistent AF | 440 (57.4) | 176 (65.9) | 264 (52.9) | <0.01 |
| Structural heart disease | 69 (9.0) | 33 (12.4) | 36 (7.2) | 0.026 |
| Congestive heart failure | 28 (3.7) | 17 (6.4) | 11 (2.2) | |
| Hypertension | 362 (47.3) | 161 (60.3) | 201 (40.3) | |
| Age ≥ 65 years | 216 (28.2) | 117 (43.8) | 99 (19.8) | |
| Age ≥ 75 years | 23 (3.0) | 13 (4.9) | 10 (2.0) | |
| Diabetes | 32 (4.2) | 15 (5.6) | 17 (3.4) | |
| Previous stroke/TIA | 69 (9.0) | 53 (19.9) | 16 (3.2) | |
| Female sex | 154 (20.1) | 75 (28.1) | 79 (15.8) | |
| Vascular disease | 74 (9.7) | 35 (13.1) | 39 (7.8) | |
| Liver and/or kidney disease | 3 (0.4) | 2 (0.7) | 1 (0.2) | |
| Bleeding | 2 (0.3) | 2 (0.7) | 0 (0.0) | |
| Drugs and/or alcohol | 90 (11.7) | 20 (7.4) | 70 (14.0) | |
| Labile INR | 122 (15.9) | 122 (45.7) | – | |
| CHADS2 score | <0.01 | |||
| ≤1 | 646 (84.3) | 188 (70.4) | 458 (91.8) | |
| ≥2 | 120 (15.7) | 79 (29.6) | 41 (8.2) | |
| ≥3 | 43 (5.6) | 34 (12.7) | 9 (1.8) | |
| CHA2DS2VASc score | <0.01 | |||
| ≤1 | 478 (62.4) | 101 (37.8) | 377 (75.6) | |
| ≥2 | 288 (37.6) | 166 (62.2) | 122 (24.5) | |
| ≥3 | 127 (16.6) | 87 (32.6) | 40 (8.0) | |
| HASBLED score | <0.01 | |||
| ≤1 | 605 (79.0) | 159 (59.6) | 446 (89.4) | |
| ≥2 | 161 (21.0) | 108 (40.4) | 53 (10.6) | |
| . | Total population n = 766 patients (%) . | ON-OAT group n = 267 patients (%) . | OFF-OAT group n = 499 patients (%) . | P value . |
|---|---|---|---|---|
| Male sex | 612 (79.9) | 192 (71.9) | 420 (84.2) | <0.01 |
| Age, years ± SD | 57 ± 11 | 61 ± 10 | 55 ± 11 | 0.021 |
| Paroxysmal AF | 326 (42.6) | 91 (34.1) | 235 (47.1) | <0.01 |
| Persistent AF | 440 (57.4) | 176 (65.9) | 264 (52.9) | <0.01 |
| Structural heart disease | 69 (9.0) | 33 (12.4) | 36 (7.2) | 0.026 |
| Congestive heart failure | 28 (3.7) | 17 (6.4) | 11 (2.2) | |
| Hypertension | 362 (47.3) | 161 (60.3) | 201 (40.3) | |
| Age ≥ 65 years | 216 (28.2) | 117 (43.8) | 99 (19.8) | |
| Age ≥ 75 years | 23 (3.0) | 13 (4.9) | 10 (2.0) | |
| Diabetes | 32 (4.2) | 15 (5.6) | 17 (3.4) | |
| Previous stroke/TIA | 69 (9.0) | 53 (19.9) | 16 (3.2) | |
| Female sex | 154 (20.1) | 75 (28.1) | 79 (15.8) | |
| Vascular disease | 74 (9.7) | 35 (13.1) | 39 (7.8) | |
| Liver and/or kidney disease | 3 (0.4) | 2 (0.7) | 1 (0.2) | |
| Bleeding | 2 (0.3) | 2 (0.7) | 0 (0.0) | |
| Drugs and/or alcohol | 90 (11.7) | 20 (7.4) | 70 (14.0) | |
| Labile INR | 122 (15.9) | 122 (45.7) | – | |
| CHADS2 score | <0.01 | |||
| ≤1 | 646 (84.3) | 188 (70.4) | 458 (91.8) | |
| ≥2 | 120 (15.7) | 79 (29.6) | 41 (8.2) | |
| ≥3 | 43 (5.6) | 34 (12.7) | 9 (1.8) | |
| CHA2DS2VASc score | <0.01 | |||
| ≤1 | 478 (62.4) | 101 (37.8) | 377 (75.6) | |
| ≥2 | 288 (37.6) | 166 (62.2) | 122 (24.5) | |
| ≥3 | 127 (16.6) | 87 (32.6) | 40 (8.0) | |
| HASBLED score | <0.01 | |||
| ≤1 | 605 (79.0) | 159 (59.6) | 446 (89.4) | |
| ≥2 | 161 (21.0) | 108 (40.4) | 53 (10.6) | |
AF, atrial fibrillation; OAT, oral anticoagulation therapy; TIA, transient ischaemic attack; INR, international normalized ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
